Human Immunoglobulin E specific for Vespula germanica venom allergens (sIgE (Vespula germanica))

Human Immunoglobulin E (IgE) antibodies specific for Vespula germanica venom allergens are the primary mediators of Type I hypersensitivity reactions to German wasp stings. These antibodies are produced following sensitization to venom components such as Ves g 1 (phospholipase A1), Ves g 2 (hyaluronidase), and Ves g 5 (antigen 5) (PMID: 8644714). In sensitized individuals, these IgE molecules occupy high-affinity FcεRI receptors on mast cells and basophils; allergen cross-linking of these antibodies triggers the release of vasoactive amines and cytokines, potentially leading to life-threatening anaphylaxis (Source: StatPearls, Hymenoptera Venom Allergy). Management of this condition involves Venom Immunotherapy (VIT), which utilizes standardized Vespula germanica venom extracts to desensitize the patient and promote the production of protective IgG4 antibodies (Source: EAACI Guidelines). Additionally, the anti-IgE antibody Omalizumab is sometimes employed to reduce the risk of adverse reactions during immunotherapy by sequestering free IgE (Source: FDA Label, Xolair).

Other names

Anti-Vespula germanica IgEGerman wasp venom-specific IgEWasp venom IgEVespula germanica sIgE

Therapeutic agents like Omalizumab bind to the Cε3 domain of the IgE molecule, preventing it from interacting with the high-affinity IgE receptor (FcεRI) on mast cells and basophils. Venom Immunotherapy (VIT) involves the administration of increasing doses of Vespula germanica venom allergens to induce immune tolerance, characterized by the production of allergen-specific IgG4 blocking antibodies and the modulation of T-cell responses from Th2 to Th1/Treg profiles.